Mr. Mongon will become CEO of Johnson & Johnson’s standalone consumer health company, and Paul Ruh will remain in his current role of chief financial officer, according to a company announcement May 11.
Mr. Mongon, who served as executive vice president and worldwide chairman of consumer health at Johnson & Johnson since 2019, will transition to his position upon completion of the planned separation of the consumer health business, expected to occur within 2023.
On Nov. 12, Johnson & Johnson announced the plans to split into two public companies — one for consumer health products and another for pharmaceuticals and medical devices.
The consumer health division will comprise four $1 billion megabrands and 20 brands that are each worth more than $150 million. Some include Band-Aid, Tylenol, Neutrogena and Listerine.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.